After Talks With FDA on Iluvien, Alimera Sees Need for New Trials Eliminated

Drug Industry Daily
Alimera Sciences’ negotiations with the FDA on Iluvien have put the diabetic macular edema drug on a glide path to potential approval — a startling about-face following three complete response letters (CRL) for the drug’s application.

To View This Article:


Subscribe To Drug Industry Daily